A systematic review and meta-analysis directed towards the anti-obesity effects of GLP-1R agonists further reported evidence of higher weight reduction (weighted mean difference (WMD) = −2.61), greater waist circumference reduction (WMD = −3.46) and change in body mass index (WMD = −0.93) associated with the treatment of GLP-1R agonists [79]. Here, GLP1R is linked to obesity disorder.